WallStreetZenWallStreetZen

NASDAQ: OTIC
Otonomy Inc Stock

Open Broker Account
$0.14-0.02 (-12.5%)
Updated Dec 2, 2022
OTIC Price
$0.14
Fair Value Price
$0.75
Market Cap
$8.23M
52 Week Low
$0.07
52 Week High
$2.59
P/E
-0.19x
P/B
0.38x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$52.26M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.69
Operating Cash Flow
-$47M
Beta
0.88
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

OTIC Overview

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how OTIC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

OTIC ($0.14) is undervalued by 80.86% relative to our estimate of its Fair Value price of $0.75 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
OTIC ($0.14) is significantly undervalued by 80.86% relative to our estimate of its Fair Value price of $0.75 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
OTIC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more OTIC due diligence checks available for Premium users.

Be the first to know about important OTIC news, forecast changes, insider trades & much more!

OTIC News

Valuation

OTIC fair value

Fair Value of OTIC stock based on Discounted Cash Flow (DCF)
Price
$0.14
Fair Value
$0.75
Undervalued by
81.39%
OTIC ($0.14) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
OTIC ($0.14) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
OTIC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

OTIC price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.19x
Industry
13.84x
Market
21.89x

OTIC price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.38x
Industry
5.06x
OTIC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

OTIC's financial health

Profit margin

Revenue
$0.0
Net Income
-$12.0M
Profit Margin
0%
OTIC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$57.5M
Liabilities
$36.1M
Debt to equity
1.69
OTIC's short-term assets ($43.91M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OTIC's short-term assets ($43.91M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OTIC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
OTIC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$13.0M
Investing
$10.0k
Financing
$0.0
OTIC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

OTIC vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
OTIC$8.23M-11.66%-0.19x0.38x
ATHX$8.21M+4.27%-0.08x-0.49x
PHGE$7.98M+6.40%-0.24xN/A
NAVB$8.61M-1.48%-0.47x-1.84x
DRMA$7.76M+3.39%-1.26x1.04x

Otonomy Stock FAQ

What is Otonomy's quote symbol?

NASDAQ: OTIC) Otonomy trades on the NASDAQ under the ticker symbol OTIC. Otonomy stock quotes can also be displayed as NASDAQ: OTIC.

If you're new to stock investing, here's how to buy Otonomy stock.

What is the 52 week high and low for Otonomy (NASDAQ: OTIC)?

(NASDAQ: OTIC) Otonomy's 52-week high was $2.59, and its 52-week low was $0.07. It is currently -94.44% from its 52-week high and 102.82% from its 52-week low.

How much is Otonomy stock worth today?

(NASDAQ: OTIC) Otonomy currently has 57,153,490 outstanding shares. With Otonomy stock trading at $0.14 per share, the total value of Otonomy stock (market capitalization) is $8.23M.

Otonomy stock was originally listed at a price of $17.15 in Aug 13, 2014. If you had invested in Otonomy stock at $17.15, your return over the last 8 years would have been -99.16%, for an annualized return of -44.98% (not including any dividends or dividend reinvestments).

How much is Otonomy's stock price per share?

(NASDAQ: OTIC) Otonomy stock price per share is $0.14 today (as of Dec 2, 2022).

What is Otonomy's Market Cap?

(NASDAQ: OTIC) Otonomy's market cap is $8.23M, as of Dec 5, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Otonomy's market cap is calculated by multiplying OTIC's current stock price of $0.14 by OTIC's total outstanding shares of 57,153,490.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.